FDA First-Half Approvals: 12 New Molecular Entities, 4 Biologics
This article was originally published in The Pink Sheet Daily
Executive Summary
The mid-year approval count puts the agency ahead of 2003's mid-year tally of nine NMEs, but behind the six biologics cleared in the first half of last year. FDA appears poised to beat 2003's full-year score of 21 NME approvals, with at least 32 NMEs pending.
You may also be interested in...
Organon Abandons Gepirone Following Second “Not Approvable” Letter
Company will withdraw NDA for the antidepressant, which it had planned to market as Variza. With Implanon, Organon has one potential 2004 launch remaining; other new products are not expected before 2006-2007
Genta/Aventis To Meet With FDA After Genasense NDA Withdrawal
The meeting will review key issues and identify next steps for Genasense development, Genta said. The company expects to release data from Phase III melanoma and leukemia studies throughout the year.
Genentech Avastin Approved For Colorectal Cancer With Five-Month Survival Benefit
The angiogenesis inhibitor gets full FDA approval Feb. 26. Genentech said it will begin shipping the biologic within three days.